MediWound Ltd. (MDWD) AI Stock Analysis

MediWound Ltd. develops, manufactures, and commercializes bio-therapeutic solutions aimed at tissue repair and regeneration. Its flagship product, NexoBrid, is marketed for the removal of eschar from adults with deep partial- and full-thickness thermal burns, serving burn centers and hospital burn units. The company is also advancing EscharEx, which has completed Phase II clinical trials for debriding chronic and difficult-to-heal wounds. Additionally, MediWound is developing MW005, an asset in Phase I/II clinical trials for the treatment of low-risk basal cell carcinoma. Founded in 2000 and based in Yavne, Israel, the company had 121 employees.

MediWound recorded a 5-year revenue CAGR of -4.9% from FY2020 to FY2025. Annual revenue grew to $26.5M in FY2022 before falling 29.5% to $18.7M in FY2023, rising 8.2% to $20.2M in FY2024, and dropping 16.1% to $17.0M in FY2025. Gross margin was 19.2% in FY2025, down from 49.7% in FY2022. Net income for FY2025 was -$23.9M, with a net margin of -140.8% and EPS of -$2.10. For the trailing twelve months ended June 30, 2026, revenue stood at $11.9M, with latest quarterly revenue falling 45.8% year-over-year and operating margin at -305.9%.

As of June 30, 2026, MediWound held $35.3M in cash and short-term investments against $9.5M in total debt, leaving net cash of $25.8M. Total assets were $71.9M and shareholders' equity was $35.6M, resulting in a debt-to-equity ratio of 0.27 and a current ratio of 2.32. In FY2025, operating cash flow was -$14.5M and capital expenditures were $5.5M, yielding free cash flow of -$20.0M. The company's share count increased 230.9% over 5 years.

MediWound closed at $11.85 on October 16, 2026, representing a market capitalization of $153.0M and an enterprise value of $150.4M. The stock trades at a price-to-sales multiple of 12.9x and a forward P/E of 35.0x, both above the median of its US-listed Healthcare peers of 4.1x and 17.3x, respectively. The stock stood 23.6% below its 200-day moving average and had a beta of 0.09. Over the past year, the stock fell 39.1% while the S&P 500 (SPY) gained 16.8%, and over five years it declined 50.4% versus an 83.0% increase for SPY.

MediWound carries 5 Strong Buy ratings and 1 Buy rating, with no Hold, Sell, or Strong Sell ratings. The mean price target is $30.67, which is 158.8% above the last close of $11.85. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $23.7M and EPS of -$2.23. For the following fiscal year, 5 analysts expect revenue of $31.8M and EPS of -$2.29. MediWound beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 19, 2026.

This page is an AI-written research summary of MediWound Ltd. (MDWD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MDWD income statement, MDWD balance sheet, MDWD key metrics, MDWD analyst forecast, MDWD chart. See the MDWD stock overview for the latest quote and news.